SIXTIDE
Sepsis
Pre-clinicalActive
Key Facts
About Sepsia Therapeutics
Sepsia Therapeutics, founded in 2019 and based in Barcelona, is pioneering a non-antibiotic, host-directed strategy to treat sepsis, a condition with high mortality and growing incidence. Its core technology leverages natural human scavenger receptors to neutralize pathogen toxins and modulate the immune response, aiming to bypass antibiotic resistance. The company is advancing a multi-pronged pipeline, including the lead program SIXTIDE, through preclinical and clinical development to address a critical unmet medical need.
View full company profileTherapeutic Areas
Other Sepsis Drugs
| Drug | Company | Phase |
|---|---|---|
| Point of care multiplex sepsis test | EDX Medical | Launching |
| VB-001 | VST Bio | Pre-clinical |
| Injectable Melatonin (IPR-490) | Pharmamel | Phase 2 |
| Ultrasensitive Sepsis Diagnostics | DIANA Biotechnologies | Development/Commercialization |
| EXO‑CD24 | Nano24med | Preclinical |